AV Dosing and AE Management in Patients With Untreated CLL Part 1: Diagnosis and Initial Treatment

This Case-Based Exchange marks the first installment in our 3-part series, featuring discussions on using fixed-duration acalabrutinib + venetoclax in chronic lymphocytic leukemia (CLL).

In the first video of this series, Mary Elizabeth DiLorenzo, MSN, RN, NP-BC, and Jamila Brutus, MSN, BSN, ANP-BC, RN, introduce a complex patient case to explore best practices in utilizing and managing AEs with fixed-duration acalabrutinib + venetoclax (AV) for untreated CLL. Together, their perspectives underscore the multifaceted approach needed to select the optimal treatment option for patients with CLL.

Download Transcript